| Exchange | Pair | 24h Volume | Spread | Trust | |
|---|---|---|---|---|---|
| Uniswap V4 (Ethereum) | 0X6034E0D6999741F07CB6FB1162CBAA46A1D33D36/0XCB1592591996765EC0EFC1F92599A19767EE5FFA | $954.90 | 0.61% | TRADE | |
| Uniswap V3 (Ethereum) | 0X6034E0D6999741F07CB6FB1162CBAA46A1D33D36/0X81F8F0BB1CB2A06649E51913A151F0E7EF6FA321 | $897.16 | 0.61% | TRADE |
Top 2 exchanges by 24h trading volume. BlockInsider earns affiliate commission from some exchanges listed here. Placement does not affect editorial.
What is the project about? VitaDAO, a decentralized autonomous organization, introduces VITA-FAST, an innovative funding model for longevity research. Leveraging the Ethereum blockchain, VITA-FAST are ERC-20 tokens, signifying fractional ownership of the Intellectual Property Non-Fungible Token (IP-NFT) from longevity research conducted at the Korolchuk Lab, Newcastle University.
VITA-FAST token holders gain governance rights over the IP, democratizing the decision-making processes in scientific research. 1. What is the project about? The project is focused on discovering and developing therapeutic compounds that can reactivate autophagy in Npc1 -/- cells.
This involves screening bioactive and commercial small molecules in cell survival assays to identify potential autophagy activators that are not cytotoxic. The project uses advanced techniques like luciferase-p6 clearance and Halo-GFP-LC3 orthogonal assays for this purpose.
2. What makes your project unique? The project's uniqueness lies in its approach to identifying novel compounds that can induce autophagy in NPC1 -/- cells, a crucial process for treating Niemann-Pick Type C disease. Unlike existing treatments, this project employs high-throughput screening methods and innovative assays to discover compounds with high chemical variability and no similarity to existing autophagy inducers, opening up possibilities for new iIP.
No comments yet
Be the first to share your take when accounts launch.